Treatment Strategies in Primary Vitreoretinal Lymphoma A 17-Center European Collaborative Study

A Riemens, Jacoline Bromberg, V Touitou, B Sobolewska, T Missotten, S Baarsma, C Hoyng, M Cordero-Coma, O Tomkins-Netzer, A Rozalski, I Tugal-Tutkun, Y Guex-Crosier, LI Los, JG Bollemeijer, A Nolan, J Pawade, F Willermain, B Bodaghi, N Ten Dam-Van Loon, Angela DickM Zierhut, S Lightman, F Mackensen, A Moulin, R Erckens, B Wensing, P le Hoang, H Lokhorst, Aniki Rothova

Research output: Contribution to journalArticleAcademicpeer-review

70 Citations (Scopus)

Abstract

IMPORTANCE The best treatment option for primary vitreoretinal lymphoma (PVRL) without signs of central nervous system lymphoma (CNSL) involvement determined on magnetic resonance imaging or in cerebrospinal fluid is unknown. OBJECTIVE To evaluate the outcomes of treatment regimens used for PVRL in the of subsequent CNSL. DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study was conducted at 17 referral ophthalmologic centers in Europe. We reviewed clinical, laboratory, and imaging on 78 patients with PVRL who did not have CNSL on presentation between January 1, 1991, and December 31, 2012, with a focus on the incidence of CNS manifestations during the follow-up period. INTERVENTIONS The term extensive treatment was used for various combinations of and intrathecal chemotherapy, whole-brain radiotherapy, and peripheral blood stem cell transplantation. Therapy to prevent CNSL included ocular radiotherapy and/or ocular chemotherapy (group A, 31 patients), extensive systemic treatment (group B, 21 patients), and a combination of ocular and extensive treatment (group C, 23 patients); 3 patients did not receive treatment. A total of 40 patients received systemic chemotherapy. MAIN OUTCOMES AND MEASURES Development of CNSL following the diagnosis of PVRL relative to the use or nonuse of systemic chemotherapy and other treatment regimens. RESULTS Overall, CNSL developed in 28 of 78 patients (36%) at a median follow-up of 49 months. Specifically, CNSL developed in 10 of 31 (32%) in group A, 9 of 21 (43%) in group B, and 9 of 23 (39%) in group C. The 5-year cumulative survival rate was lower in patients with CNSL (35%[95% CI, 50% to 86%]) than in patients without CNSL (68%[95% CI, 19% to 51%]; P = .003) and was similar among all treatment groups (P = .10). Adverse systemic effects occurred in 9 of 40 (23%) patients receiving systemic chemotherapy; the most common of these effects was acute renal failure. CONCLUSIONS AND RELEVANCE In the present series of patients with isolated PVRL, the use of systemic chemotherapy was not proven to prevent CNSL and was associated with more severe adverse effects compared with local treatment.
Original languageUndefined/Unknown
Pages (from-to)191-197
Number of pages7
JournalJAMA Ophthalmology
Volume133
Issue number2
DOIs
Publication statusPublished - 2015

Cite this